David Paul Kelsen, MD
Gastrointestinal Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Colorectal, Esophageal, Gallbladder, Pancreatic, and Other Gastrointestinal Cancers
- Neuroendocrine Tumors
- Unknown Primary Tumors
About Me
- Edward S. Gordon Chair in Medical Oncology
I am a board-certified medical oncologist with clinical and research interests in the field of gastrointestinal malignancies. My clinical practice includes care of patients with gastrointestinal cancers, neuroendocrine tumors, and cancers of unknown primary site.
I am an attending physician on the Gastrointestinal Oncology Service, which I was privileged to lead as Chief from 1991 to 2011. I also serve on Memorial Sloan Kettering Cancer Center’s Research Council, which oversees our clinical research portfolio, among other committees.
Read more
My research is focused on upper gastrointestinal cancers, particularly pancreatic and gastroesophageal cancers. Our group’s clinical and translational studies are designed to develop a better understanding of the driving factors in the development of these malignancies, particularly on the genomic level. Our research suggests that gastroesophageal and pancreas cancers are not one disease and that by characterizing the different subtypes, we will be able to develop better prevention, early diagnosis, staging, and treatment strategies. For example, I lead our registry to study inherited BRCA mutation-related pancreas cancer. Our translational research includes projects aimed at the identification of new biomarkers, based on molecular profiling of the different subtypes, which could help in choosing the specific treatment for individual patients. I have been the Principal Investigator of national phase II and III clinical trials. My research has been supported by grants from the National Cancer Institute, the American Cancer Society, and the Lustgarten Foundation.
Nationally, I have served as a member of the Oncology Drug Advisory Committee of the US Food and Drug Administration, the GI Committee of the Radiation Therapy Oncology Group, and the Investigational Drugs Steering Committee of the Cancer Therapy Evaluation Program of the National Cancer Institute. I am currently the co-chair of the Clinical Trials subcommittee of the Lustgarten Foundation for Pancreatic Cancer Research.
A gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers, as well as GI stromal tumors and neuroendocrine tumors.
My Specialties
- Colorectal, Esophageal, Gallbladder, Pancreatic, and Other Gastrointestinal Cancers
- Neuroendocrine Tumors
- Unknown Primary Tumors
Education
- MD, Hahnemann University School of Medicine
Residencies
- Temple University Hospital
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
Fellowships
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Kelsen sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Kelsen
- A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Kelsen’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David Paul Kelsen discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
Acrotech Biopharma
Professional Services and Activities -
Aummune
Professional Services and Activities -
Blueprint Medicines
Professional Services and Activities -
Bristol-Myers Squibb
Professional Services and Activities -
Daiichi Sankyo
Professional Services and Activities -
GlaxoSmithKline
Professional Services and Activities
-
Guardant Health, Inc.
Professional Services and Activities -
Incyte
Professional Services and Activities -
Janssen Pharmaceuticals, Inc.
Professional Services and Activities -
Merck Sharp & Dohme
Professional Services and Activities -
NeoTX Therapeutics Ltd.
Professional Services and Activities -
Oncopeptides AB
Professional Services and Activities -
TG Therapeutics, Inc
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].